Two new programs are now available, including a First Fill Free initiative via pharmacy partner BlinkRx and an in-office dispensing choice, providing eye care professionals with additional tools to assist patients in beginning and continuing Qlosi therapy.

Fifteen months after launch, Qlosi refill rates have reached 49 percent, roughly double the levels often seen at retail pharmacies for dry eye prescription treatments.

Orasis Pharmaceuticals, an ophthalmic pharmaceutical company focused on innovative vision solutions, has introduced two new programs to support eye care professionals and patients using Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4 percent. The First Fill Free option, available through pharmacy partner BlinkRx, allows patients to receive their initial fill at no cost following a prescription from their eye care professional, followed by standard pricing. Qlosi is also now offered for in-office dispensing in states where allowed. Combined with home delivery through BlinkRx, these choices give eye care professionals and their patients expanded access to Qlosi while underscoring Orasis' emphasis on an optometry-centered model for presbyopia management.

Since its U.S. launch in April 2025, Qlosi has gained consistent traction. Thousands of eye care professionals are now prescribing the treatment, and refill rates have climbed to 49 percent, about twice the typical rates seen with dry eye prescription therapies at retail pharmacies. This indicates patients are experiencing noticeable improvements in near vision and opting to continue therapy. No retinal tears or detachments have been reported to the FDA, and real-world results align with the efficacy, tolerability, and safety profiles observed in the pivotal Phase 3 trials.

"Our aim has always been to enable patients to see clearly up close without needing readers," said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals. "We designed Qlosi with eye care professionals in mind rather than pursuing a direct-to-patient telehealth route. The First Fill Free program through BlinkRx and in-office dispensing provide eye care professionals and patients with more access options, while the 49 percent refill rate, nearly double the norm for dry eye prescription therapies at retail, confirms patients are achieving meaningful benefits and electing to remain on treatment."

Both options preserve the prescribing relationship between the patient and their eye care professional. First Fill Free and home delivery are handled through BlinkRx, whereas in-office dispensing allows patients to depart the appointment with the medication in states where permitted.

"The efficacy, tolerability, and safety I observe in my practice align with the clinical trial data, and my patients are grateful for an alternative to readers. A no-cost first fill through BlinkRx lowers the hurdle to starting therapy, and stocking Qlosi in the office enables me to initiate treatment for the appropriate patient during the visit, which suits my approach," said David Rouse, OD, FAAO, of Rouse Family Eye Care, SECO President, and Chair of the Florida Board of Optometry.

For additional details on the First Fill Free program through BlinkRx and prescribing Qlosi, visit the dedicated eye care professional site. To arrange Qlosi for in-office dispensing, refer to the in-office ordering page. Eye care professionals may also reach their Orasis Key Account Manager.

About Presbyopia

Presbyopia involves the gradual loss of ability to focus on near objects due to the natural aging process. It typically begins after age 40 as the crystalline lens stiffens and loses flexibility. Nearly two billion people worldwide and over 128 million in the U.S. are affected. Individuals with presbyopia notice blurred vision during tasks requiring near focus, such as reading or using a smartphone. The condition cannot be prevented or reversed and progresses slowly. Many current treatments are either cumbersome or invasive, highlighting an unmet need. Diagnosis occurs during an eye exam by an eye care professional.

About Qlosi

Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4 percent is a novel prescription eye drop approved in the U.S. for treating presbyopia in adults. Its EyeQ Formulation delivers the lowest effective pilocarpine concentration in a preservative-free drop with near-neutral pH and dual lubricating agents for improved safety and comfort without sacrificing efficacy. Qlosi enhances near visual acuity through pupil modulation, creating a pinhole effect that increases depth of field. In clinical trials, the most common treatment-related adverse events were headache and instillation site pain, occurring at 6.8 percent and 5.8 percent, respectively.

About Orasis Pharmaceuticals

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to reshaping vision possibilities. It developed Qlosi, a novel corrective prescription eye drop for presbyopia in adults. The company is led by a team of industry executives and eye care professionals committed to advancing the standard of care for near vision correction. Orasis is supported by experienced life science and healthcare investors and maintains offices in the United States and Israel.

About BlinkRx

BlinkRx is transforming the pharmacy experience through integrated, data-driven technology that enhances patient access to branded medications. Its prescription journey management platform simplifies each step, benefiting all stakeholders. Patients receive the lowest network price, free home delivery, and personalized support. Healthcare providers gain dedicated access teams and improved prior authorization assistance. Pharmacies access tools to better serve patients, and manufacturers obtain greater transparency from prescription to fulfillment.

Qlosi U.S. Indication and Important Safety Information

Indication and Usage

Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4 percent, for topical ophthalmic use, is a cholinergic agonist indicated for the treatment of presbyopia in adults.

Important Safety Information

CONTRAINDICATIONS

Hypersensitivity

WARNINGS AND PRECAUTIONS

Advise patients to avoid driving or operating machinery if vision is unclear, such as with blurred vision. Use caution during night driving and other hazardous activities in low light.
Rare cases of retinal detachment have been reported with miotics. Retinal examination is recommended for all patients before starting therapy. Patients should seek immediate medical attention for sudden flashes of light, floaters, or vision loss.
Qlosi is not recommended when iritis is present.
Qlosi should not be used while wearing contact lenses. Remove lenses before instillation and wait 10 minutes before reinsertion.
Avoid touching the vial tip to the eye or any surface.

ADVERSE REACTIONS

The most common adverse reactions (5 percent to 8 percent) are instillation site pain and headaches.

Please see full Prescribing Information for complete details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Media Contact: [email protected]

References:

1 Data on file.

2 Young, Kate. Patients with DED prescribed Miebo have higher refills rates than those on cyclosporine. Primary Care Optometry News. June 24, 2024.

3 FDA Adverse Events Monitoring System (AEMS) Public Dashboard for Drugs and Biologics. Accessed July 20, 2026.

4 Holland E, Karpecki P., Fingeret M., et al. Efficacy and Safety of CSF-1 (0.4 percent Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005.

5 Holden, B. A., et al. Global Vision Impairment Due to Uncorrected Presbyopia. 2008;126(12):1731-1739.

6 U.S. Census Bureau. United States Census - Populations and People. July 20, 2026.

7 WebMD. Presbyopia: Symptoms, diagnosis, and treatment. Accessed July 20, 2026.

8 U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed July 20, 2026.

9 Qlosi [package insert]. Ponte Verda, FL. Orasis Pharmaceuticals.

SOURCE ORASIS PHARMACEUTICALS